Clinical Trials Logo

Fontan clinical trials

View clinical trials related to Fontan.

Filter by:
  • None
  • Page 1

NCT ID: NCT04297241 Completed - Fontan Clinical Trials

Nitrate Effect on Exercise Capacitance

NEET
Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

The investigators will investigate the safety and preliminary efficacy of ISDN therapy to reduce venous congestion and improve exercise tolerance in children and adults after the Fontan operation. This will be accomplished by recruiting 15 Fontan physiology patients from the Cincinnati Children's Fontan clinic and University of Kentucky Pediatric Cardiology clinic for the investigation. The investigators will non-invasively measure both central venous pressures at rest and during graded cardiopulmonary exercise testing. In addition the study team will obtain a measurement of liver stiffness before and after a 4-week regimen of ISDN therapy. Patients will be seen twice in clinic, once before and after ISDN therapy, and phone calls will be made to ensure safety, compliance, and make appropriate alterations to medications throughout the study period. Pre- and post-intervention central venous pressure and exercise tolerance will be compared.

NCT ID: NCT04288596 Not yet recruiting - Clinical trials for Patent Foramen Ovale

Canadian Adult Congenital Heart Disease Intervention Registry

C-ACHDiR
Start date: April 1, 2020
Phase:
Study type: Observational [Patient Registry]

The ACHDi Registry study will create a foundational database for adult congenital heart disease interventions. This Pan-Canadian Registry will collect clinical and patient-reported information that will enable the evaluation of care processes and outcomes in five most common ACHDi interventions by enabling prospective and retrospective registry-based studies to answer important clinical practice and policy-relevant questions.

NCT ID: NCT03965351 Completed - Fontan Clinical Trials

TRPV2 Agonists in the Fontan Circulation

Start date: March 21, 2017
Phase: Phase 4
Study type: Interventional

There are currently very few proven pharmacologic options available for these patients. The recent discovery of transient receptor potential vanilloid (TRPV) channels, particularly TRPV2 channels, in the cardiovascular system is promising as a potential pathway for pharmacologic intervention for Fontan patients. Probenecid, a drug best known as a treatment for gout or as a penicillin adjunct, acts as a TRPV2 agonist and has recently become the subject of study as a model therapy for the treatment of cardiomyopathy due to its positive inotropic and lusitropic effects. The purpose of this pilot study is to determine if probenecid will improve magnetic resonance (MRI) parameters of systolic and/or diastolic dysfunction as well as associated symptoms in patients with a Fontan circulation. The investigators will quantitatively assess functional improvement with pre- and post-treatment cardiopulmonary exercise testing.

NCT ID: NCT02946892 Completed - Single Ventricle Clinical Trials

Effect of Carvedilol on Exercise Performance in Fontan Patients

Start date: November 2016
Phase: Phase 4
Study type: Interventional

This study evaluates the effect of carvedilol in patients who have undergone a Fontan heart operation. All participants will receive carvedilol and placebo for 12 weeks. Exercise tests will be performed at the end of each 12 week period.

NCT ID: NCT01607983 Withdrawn - Clinical trials for Congenital Heart Disease

Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients

Start date: June 2012
Phase: Phase 3
Study type: Interventional

The study involves documenting the effects of inhaled nitric oxide upon ventricular-arterial coupling in patients with congenital heart disease and passive pulmonary blood flow. Consenting patients undergoing a clinically-indicated cardiac catheterization will be given inhaled nitric oxide for 10 minutes while intraventricular pressure-volume analysis will be make via conduction catheters.